Characteristics | Total Cohort, n = 203 | No Preceding Malignancy, n = 187 | Preceding Malignancy, n = 16 | p* |
---|---|---|---|---|
Age at diagnosis, yrs (mean ± SD) | 55.7 ± 16.5 | 54.6 ± 16.7 | 68.4 ± 5.6 | < 0.001 |
Male, n (%) | 132 (65.0) | 118 (63.1) | 14 (87.5) | 0.05 |
Followup, yrs (mean ± SD) | 12.1 ± 6.6 | 11.9 ± 6.5 | 14.3 ± 6.5 | 0.17 |
Diagnosis, n (%) | 0.53** | |||
GPA | 120 (59.1) | 109 (58.3) | 11 (68.8) | |
MPA | 62 (30.6) | 58 (31.0) | 4 (25.0) | |
Unknown | 21 (10.3) | 20 (10.7) | 1 (6.2) | |
ANCA serotype, n (%) | 0.69† | |||
PR3-ANCA | 79 (38.9) | 74 (39.6) | 5 (31.4) | |
MPO-ANCA | 84 (41.4) | 76 (40.6) | 8 (50.0) | |
ANCA-negative | 12 (5.9) | 11 (5.9) | 1 (6.2) | |
Double-positive | 5 (2.5) | 4 (2.1) | 1 (6.2) | |
Unknown | 23 (11.3) | 22 (11.8) | 1 (6.2) |
↵* Patients with a preceding malignancy versus patients without a preceding malignancy. Preceding malignancy was defined as any primary invasive, histopathologically confirmed malignancy that occurred between 1989 and the diagnosis of AAV.
↵** P value refers to the comparison between GPA and MPA subgroups.
↵† P value refers to the comparison between PR3-ANCA and MPO-ANCA positive subgroups. GPA: granulomatosis with polyangiitis; MPA: microscopic polyangiitis; ANCA: antineutrophil cytoplasmic antibodies; PR3-ANCA: proteinase 3 ANCA; MPO-ANCA: myeloperoxidase ANCA.